News | February 04, 2008

Drs. Perform First Mitralign Percutaneous Annuloplasty System Implant

February 5, 2008 – A medical team led by Adrian Ebner, M.D., of French Hospital and Lutz Buellesfeld, M.D. of Helios Heart Center, Siegburg, Germany, performed the first implantation of the Mitralign Percutaneous Annuloplasty System for mitral valve repair at French Hospital in Asuncion, Paraguay.

The Mitralign System was able to remodel the valve and reduce the patient’s mitral regurgitation from 3 to 2 , 24 hours after the procedure based on core lab assessment. The patient spent less than 48 hours in the hospital after the procedure and continues to do well at home.

The Mitralign System emulates the open surgical procedure of suture-based mitral annuloplasty. The implant was percutaneously delivered through a single 14F femoral arterial sheath, and provides direct geometric reduction of the posterior annulus. commented on the system’s clear impact on the mitral valve geometry.
"I have been involved with a number of mitral valve repair approaches; this approach is most exciting because it delivers on its promise to affect the valve on demand," said Dr. Ebner.

The case will be presented at two conferences this month, Cardiovascular Revascularization Therapies in Washington, D.C., by Prof. Dr. med. Eberhard Grube and the Joint Interventional Meeting, in Rome, Italy, by Paul Teirstein, M.D.

For more information: www.mitralign.com

Related Content

New Consensus Document Explores Optimized Care for Valvular Heart Disease Patients
News | Heart Valve Technology | April 22, 2019
April 22, 2019 — Five cardiovascular professional societies released a new consensus document on optimizing care for
Mick Jagger Recovering After TAVR Procedure
News | Heart Valve Technology | April 08, 2019 | Jeff Zagoudis, Associate Editor
Rolling Stones frontman Mick Jagger is reportedly recovering after undergoing a transcatheter aortic valve valve...
 Evolut Low Risk Trial compared the minimally invasive Evolut transcatheter aortic valve replacement (TAVR) system to the gold standard of open-heart surgery in characteristically younger, healthier aortic stenosis patients. The randomized trial, which met its primary non-inferiority endpoint of all-cause mortality or disabling stroke at two years compared to surgery (5.3 vs. 6.7 percent; posterior probability of non-inferiority >0.999), was presented at the American College of Cardiology (ACC) 2019 meeting
News | Heart Valve Technology | April 03, 2019
April 3, 2019 – The ACC.19 late-breaking landmark Evolut Low Risk Trial compared the minimally invasive Evolut transc
TAVR Outperforms Surgery in Younger, Low-Risk Aortic Stenosis Patients
News | Heart Valve Technology | March 22, 2019
Among patients with severe symptomatic aortic stenosis at low surgical risk, transcatheter aortic valve replacement (...
ACC Launches Transcatheter Valve Certification
News | Heart Valve Technology | March 14, 2019
March 14, 2019 — Beginning in mid-2019, hospitals performing...
FDA Approves MitraClip for Use in Heart Failure Patients With Functional Mitral Regurgitation
Feature | Heart Valve Technology | March 14, 2019 | Jeff Zagoudis, Associate Editor
March 14, 2019 — The U.S.
Scientists Discover New Type of Immune Cells Essential for Forming Heart Valves

Microscopic images of a normal heart valve in a mouse, left, and a heart valve grown in a lab with heart-derived macrophages blocked, right. Without those macrophages, the valves are thick and deformed. Image courtesy of Developmental Cell/UCLA Broad Stem Cell Research Center.

News | Heart Valve Technology | March 06, 2019
UCLA researchers have identified for the first time the origin of an immune cell that plays a critical role in the...
Overlay Init